GlassScriptPhysician profile
Anis Ahmadi
NPI 1932270832
$6,999.53
in general payments reported to CMS, 2019-2025
34 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $226 · 2021: $650 · 2022: $998 · 2023: $1,228 · 2024: $1,633 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527 · Education: $23.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.30 |
| Education | $23.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.66 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $600.92 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $597.96 | 2020-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.12 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Madrigal Pharmaceuticals | $448.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $247.63 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $242.09 | 2022-2025 | |
| Celgene Corporation | $240.42 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $200.20 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $191.93 | 2021-2025 | |
| Lilly USA, LLC | $188.26 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $186.12 | 2021-2024 | Dificid, Zerbaxa, Zinplava |
| Braintree Laboratories, INC. | $132.36 | 2019-2023 | Sutab, Suflave |
| Medtronic, INC. | $121.62 | 2022 | |
| Ironwood Pharmaceuticals, INC | $102.19 | 2020-2024 | Linzess |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $101.10 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $85.26 | 2021 | |
| Pfizer INC. | $73.98 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $71.53 | 2024-2025 | Givlaari |
| Enterra Medical, INC. | $68.08 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $63.45 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $61.47 | 2021-2023 | Injectafer |
| Evoke Pharma, INC. | $41.63 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $39.74 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $35.84 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $34.23 | 2021-2023 | Ocaliva |
| Celltrion USA INC. | $23.92 | 2024 | Zymfentra |
| Pentax of America, INC. | $19.90 | 2020 | |
| Pharmacosmos Therapeutics INC. | $19.74 | 2022 | |
| Vivus LLC | $19.11 | 2021 | |
| Shionogi INC | $18.10 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.30 | 2019 | |
| Alfasigma USA, INC. | $13.16 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anis Ahmadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.